Apoptotic cell death is a hallmark of the loss of insulin-producing beta cells in all forms of diabetes mellitus. Current treatments fail to halt the decline in functional beta cell mass, and strategies to prevent beta cell apoptosis and dysfunction are urgently needed. Here, we identified mammalian sterile 20-like kinase-1 (MST1) as a critical regulator of apoptotic beta cell death and function. Under diabetogenic conditions, MST1 was strongly activated in beta cells in human and mouse islets and specifically induced the mitochondrial-dependent pathway of apoptosis through upregulation of the BCL-2 homology-3 (BH3)-only protein BIM. MST1 directly phosphorylated the beta cell transcription factor PDX1 at T11, resulting in the latter's ubiquitination and degradation and thus in impaired insulin secretion. MST1 deficiency completely restored normoglycemia, beta cell function and survival in vitro and in vivo. We show MST1 as a proapoptotic kinase and key mediator of apoptotic signaling and beta cell dysfunction and suggest that it may serve as target for the development of new therapies for diabetes.
Pancreatic beta cell death is the fundamental cause of type 1 diabetes (T1D) and a contributing factor to the reduced beta cell mass in type 2 diabetes (T2D) [1] [2] [3] [4] . In both cases, the mechanisms of beta cell death are complex and as yet not fully defined. Thus, multiple triggering factors have been identified; these factors initiate a variety of signaling cascades that affect the expression of apoptotic genes, leading to subsequent beta cell failure. In T1D, autoimmune destruction of insulin-producing beta cells and critically diminished beta cell mass are hallmarks of the disease 2 . Beta cell destruction occurs through immune-mediated processes; mononuclear cell infiltration in the pancreatic islets and interaction between antigen-presenting cells and T cells lead to high local concentrations of inflammatory cytokines, chemokines, reactive oxygen species and other apoptotic triggers (for example, the perforin and Fas-Fas ligand systems) 2 . In T2D, beta cell dysfunction and reduced beta cell mass are the ultimate events leading to the development of clinically overt disease in insulin-resistant individuals. Beta cell destruction is caused by multiple stimuli including glucotoxicity, lipotoxicity, proinflammatory cytokines, endoplasmic reticulum stress and oxidative stress 5 . Unfortunately, although it has been demonstrated that even a small amount of preserved endogenous insulin secretion has great benefits in terms of clinical outcome 6 , none of the currently widely used antidiabetic agents target the maintenance of endogenous beta cell mass.
Beta cells are highly sensitive to apoptotic damages induced by multiple stressors such as inflammatory and oxidative assault, owing at least in part to their low expression of cytoprotective enzymes 7 . The initial trigger of beta cell death still remains unclear; it follows an orchestra of events, which makes the initiation of beta cell death complex and its blockade difficult to successfully achieve in vivo. Therefore, the identification of a common key regulator of beta cell apoptosis would offer a new therapeutic target for the treatment of diabetes.
The identification of the genes that regulate apoptosis has laid the foundation for the discovery of new drug targets. MST1 (also known as STK4 and KRS2) is a ubiquitously expressed serine-threonine kinase that is part of the Hippo signaling pathway and involved in multiple cellular processes such as morphogenesis, proliferation, stress response and apoptosis 8, 9 . MST1 is a target and activator of caspases, serving to amplify the apoptotic signaling pathway 10, 11 . Thr183 in subdomain VIII of MST1 has been defined as a primary site for the phosphoactivation and the autophosphorylation of MST1 and is essential for kinase activation. Both phosphorylation and caspase-mediated cleavage are required for full activation of MST1 during apoptosis. MST1 promotes cell death through regulation of multiple downstream targets such as LATS1 and LATS2, histone H2B and members of the FOXO family, as well as through induction of stress kinase c-Jun-N-terminal kinase (JNK) and activation of caspase- 3 (refs. 9,12,13) .
Genetic mutations and/or metabolic disturbances can alter protein networks and thereby disrupt downstream signaling pathways that are essential for beta cell survival and function. The transcription factor pancreatic duodenal homeobox-1 (PDX1, previously called IPF1, IDX1, STF1 or IUF1) 14, 15 is a key mediator of beta cell development and function 16 . In humans, mutations in the PDX1 gene can predispose individuals to develop maturity onset diabetes of the young, type 4 (MODY 4) 17 , suggesting a critical role for PDX1 in a r t i c l e s 3 8 6 VOLUME 20 | NUMBER 4 | APRIL 2014 nature medicine mature beta cells; reduced PDX1 expression affects insulin production and secretion and predisposes to beta cell apoptosis 16, 18 . Because MST1 acts as common mediator in multiple apoptotic signaling pathways, we hypothesized that it is an initiating trigger of apoptotic signaling in beta cells. MST1 depletion completely restored normogylcemia and insulin secretion and prevented diabetes progression. These findings suggest that MST1 could be a fundamental target for diabetes therapy.
RESULTS

MST1 is activated in diabetes
To test whether MST1 activation is correlated with beta cell apoptosis, we exposed isolated human and mouse islets and the rat beta cell line INS-1E to a complex diabetogenic milieu. MST1 activity was highly upregulated in these cells under these conditions (created through incubation with the cytokines interleukin-1β (IL-1β) and interferon-γ (IFN-γ) (IL/IF), upon chronic exposure to increasing glucose concentrations (22.2 and 33.3 mM) or palmitic acid, or upon exposure to acute oxidative stress from hydrogen peroxide) ( Fig. 1a-c and Supplementary Fig. 1a,b) . The upregulation of MST1 occurred by both caspase-mediated cleavage and autophosphorylation (yielding MST1 phosphorylated on T183 (pMST1)). This was accompanied by higher phosphorylation of histone H2B as well as induction of JNK signaling ( Fig. 1a-c) . In contrast, short-term culture with high glucose concentrations (11.2, 22.2 and 33.3 mM) induced neither apoptosis nor MST1 cleavage and phosphorylation ( Supplementary  Fig. 1d ). MST1 was also activated in islets from subjects with T2D ( Fig. 1d) , obese diabetic Lepr db mice (db/db mice, Fig. 1e ) and hyperglycemic mice fed with a high-fat, high-sucrose diet (HFD) for 16 weeks (Supplementary Fig. 1c ). This activation correlated directly with beta cell apoptosis as described previously 19 , as whenever MSTI was induced, apoptosis was also higher. To confirm the beta cellspecific upregulation of MST1, we performed double immunostaining for pMST1 and insulin in pancreatic islets from subjects with poorly controlled T2D ( Fig. 1d ) and pancreatic islets from db/db mice ( Fig. 1e ) and found pMST1 staining in beta cells, whereas there was almost no signal in cells from subjects without diabetes or control mice.
Caspase-3 and JNK act not only as downstream targets but also as upstream activators of MST1 through cleavage-and phosphorylation-dependent mechanisms 12, 20 , and they may initiate a vicious cycle and a proapoptotic signaling cascade in beta cells. Using inhibitors of JNK (SP600125) and caspase-3 (z-DEVD-fmk) and siRNA to caspase-3, we found that both JNK and caspase-3 were responsible for stress-induced MST1 cleavage by diabetic stimuli in human islets and INS-1E cells ( Supplementary Fig. 1e-h ), suggesting that MST1 induces a positive feedback loop with caspase-3 under diabetogenic conditions. Because phosphatidylinositol-3 kinase (PI3K)-AKT signaling is a key regulator of beta cell survival and function 21, 22 and MST1 signaling is negatively regulated by this pathway in other cell types 23, 24 , we hypothesized that AKT is an important negative regulator of MST1. Maintaining AKT activation through either exogenous addition of mitogens such as glucagon-like peptide-1 (GLP1) or insulin or overexpression of constitutively active AKT1 (Myr-AKT1, containing a myristoylation sequence and HA tag) inhibited glucoseand cytokine-induced phosphorylation of MST1, MST1 cleavage and apoptosis ( Fig. 1f and Supplementary Fig. 2a-d) . As GLP1 and insulin exert their cell survival actions primarily through the PI3K-AKT pathway 21, 25 , we tested whether inhibition of this prosurvival signaling might enhance MST1 activation. PI3K and AKT were inhibited by LY294002, and triciribine (an AKT inhibitor) led to lower levels of phosphorylation of Gsk3 and Foxo1, two wellcharacterized AKT substrates, and induced MST1 activation (Fig. 1g,h and Supplementary Fig. 2e ). We further corroborated these findings using siRNA against AKT, which led to a critical upregulation of MST1 activity and potentiated cytokine-induced phosphorylation of MST1 and beta cell death (Supplementary Fig. 2f ). MST1 overexpression also diminished insulin-induced AKT phosphorylation and, conversely, there was higher AKT phosphorylation in MST1-depleted beta cells ( Fig. 1i) . Knockdown of MST1 expression antagonized the apoptotic effect of AKT inactivation in INS-1E cells, implicating endogenous MST1 in the apoptotic mechanism induced by PI3K-AKT inhibition ( Supplementary Fig. 2g,h) . In summary, these results suggest that MST1 is activated in prodiabetic conditions in vitro and in vivo, antagonized by PI3K-AKT signaling and dependent on the JNK-and caspase-induced apoptotic machinery.
MST1 induces beta cell death MST1 overexpression alone was also sufficient to induce apoptosis in human and rat beta cells ( Fig. 2a-c) . To investigate pathways that potentially contribute to MST1-induced beta cell apoptosis, we overexpressed MST1 in human islets and rat INS-1E cells through an adenoviral system, which efficiently upregulated MST1, activated JNK and induced beta cell apoptosis, as determined by an increased number of TUNEL-positive beta cells as well as caspase-3 activation and cleavage of poly-(ADP-ribose) polymerase (PARP), a downstream substrate of caspase-3 ( Fig. 2a-c) . Previous data proposed a role for the mitochondrial pathway in MST-dependent signaling 26, 27 . Evaluation of established mitochondrial proteins in MST1overexpressing islets and INS-1E cells showed cleavage of the initiator caspase-9, release of cytochrome c, induction of proapoptotic BAX and a decline in antiapoptotic BCL-2 and BCL-xL levels (Fig. 2b,c and Supplementary Fig. 3a) , which led to a reduction of BCL-2/BAX and BCL-xL/BAX ratios. Notably, MST1-induced caspase-3 cleavage was reduced by treatment of human islets with the Bax inhibitor peptide V5 ( Fig. 2d) , which has been shown to promote beta cell survival 28 ; together, these findings emphasize that MST1-induced apoptosis proceeds via the mitochondrial-dependent pathway. We also analyzed the expression of BH3-only proteins as regulators of the intrinsic cell death pathway 29 . Of these, BIM was robustly induced, whereas other BH3-only protein levels remained unchanged (Fig. 2b,c and Supplementary Fig. 3b ). To assess whether kinase activity of MST1 is required for altering mitochondrial-dependent proteins and induction of apoptosis, we overexpressed a kinase-dead mutant of MST1 (K59R; dominant-negative MST1 (ref. 30)) in human islets. Unlike wild-type (WT) MST1, MST1-K59R did not change the levels of BIM, BAX, BCL-2, BCL-xL and caspase-3 cleavage ( Supplementary Fig. 3c ). We next determined whether BIM is a major molecule whose action would override the proapoptotic action of MST1. Indeed, BIM depletion led to a significant reduction of MST1-induced apoptosis in human islets ( Fig. 2e,f) .
Overexpression of MST1 further potentiated glucose-induced apoptosis in beta cells in a BIM-dependent manner (Supplementary Fig. 3d ). BIM is regulated by the JNK 31 and AKT 32 signaling pathways. MST1induced increase in BIM and subsequent caspase-3 cleavage was prevented by JNK inhibition through overexpression of dn-JNK1 ( Fig. 2g ) or by the JNK inhibitor ( Supplementary Fig. 3e ), which suggests that MST1 uses JNK signaling to mediate BIM upregulation and induction of apoptosis. We confirmed the involvement of AKT in the regulation of MST1-induced apoptosis by overexpressing ) Activated MST1 in islets. Human isolated islets from nondiabetic control subjects (n = 7) and subjects with T2D (n = 4, all with documented fasting plasma glucose >150 mg/dl) (d) and from 10-week-old diabetic db/db mice (n = 5) and their heterozygous littermates (db/+, n = 5) (e). Left, western blots of MST1 and pMST1 and densitometry analyses. Right, double immunostaining for pMST1 (red) and insulin (green) in sections from human isolated islets from nondiabetic control subjects and subjects with T2D and from 6-week-old diabetic db/db mice (representative analyses from 10 pancreases from subjects with T2D and >10 pancreases from control subjects and from 7 db/db mice and 7 heterozygous controls are shown). Scale bar, 100 µm. both MST1 and Myr-AKT1, which reduced BIM induction and caspase-3 cleavage ( Fig. 2h) , indicating that AKT negatively regulates the downstream target of MST1. These data suggest that MST1 is a critical mediator of beta cell apoptosis through activation of the BIM-dependent intrinsic apoptotic pathway and controlled by AKT and JNK signaling pathways.
MST1 impairs beta cell function by destabilizing PDX1
We hypothesized that MST1 activation may elicit changes in beta cellspecific gene transcription that initiate the process of beta cell failure. Overexpression of MST1 led to a complete loss of glucose-stimulated insulin secretion (GSIS; Fig. 3a and Supplementary Fig. 4a ), which could not be accounted for solely by the induction of apoptosis.
Previously, we noted that the critical beta cell transcription factor PDX1, which mediates glucose-induced insulin gene transcription in mature beta cells 16, 18 , is mislocalized and reduced in diabetes 19 . These changes are subsequently associated with impaired beta cell function and hyperglycemia. Stress-induced kinases such as JNK and glycogen synthase kinase-3 (GSK3) phosphorylate PDX1, antagonizing its activity 33, 34 , which leads to beta cell failure. Thus, we hypothesized that the drastic reduction in insulin secretion following MST1 overexpression may be mediated by PDX1. PDX1 levels were markedly reduced in response to MST1 overexpression in human islets ( Fig. 3b ) and INS-1E cells (Supplementary Fig. 4b ). In contrast, MST1 overexpression did not affect the amount of mRNA encoding PDX1 ( Fig. 3b and Supplementary Fig. 4b ), suggesting that MST1 may regulate PDX1 at the post-transcriptional level. Analysis of PDX1 target genes demonstrated that overexpression of MST1 significantly downregulated INS (Ins1 or Ins2 for INS-1E), SLC2A2 and GCK in human islets ( Fig. 3b ) and INS-1E cells (Supplementary Fig. 4b ). Although SLC2A2 is not the predominant glucose transporter in human beta cells 35 , we analyzed its expression to provide comparison to the mouse data.
To gain better insight into the role of MST1 in regulation of insulin secretion, we performed GSIS using two insulin secretagogues: GLP1 and glibenclamide. MST1 overexpression significantly abolished GLP1-enhanced glucose-induced insulin secretion (P < 0.05 compared to control condition), whereas glibenclamide-induced insulin secretion was not affected, suggesting that defective insulin secretion may occur at a step upstream of calcium influx (Supplementary Fig. 4c ). npg MST1 overexpression had no effect on insulin content ( Fig. 3a and Supplementary Fig. 4a ), and thus insulin secretion was normalized on insulin content.
To clarify the mechanism by which MST1 regulates PDX1, we examined the effects of ectopic expression of MST1 and PDX1 in human embryonic kidney (HEK) 293 cells. We found lower PDX1 levels in cells co-overexpressing WT MST1, whereas the kinase-dead MST1-K59R had no effect ( Fig. 3c) . Thus, kinase activity is required for MST1-induced PDX1 degradation. Overexpression of MST1 also attenuated the transcriptional activity of PDX1 on the rat insulin promoter (RIP), as shown by luciferase assays in PDX1-overexpressing HEK 293 and INS-1E cells (Supplementary Fig. 4d ). Insulin content (µU/µg protein) To discriminate between a transcriptional or translational and a post-translational effect of MST1 on PDX1, we followed the stability of overexpressed PDX1 upon treatment with cycloheximide (CHX), an inhibitor of protein translation. Upon CHX exposure, PDX1 protein levels rapidly decreased when coexpressed with MST1 ( Fig. 3c) , which suggests that MST1 reduced PDX1 protein stability. Consistent with these observations, MST1 overexpression also decreased protein stability of endogenous PDX1 in human islets (Supplementary Fig. 4e ). In contrast, treatment of PDX1overexpressing HEK 293 cells with the proteasome inhibitor MG-132 reduced the disappearance of PDX1 (Fig. 3c) , indicating that MST1 induced activation of the ubiquitin proteasome pathway. Proteasomal degradation of PDX1 has been described before and leads to impaired beta cell function and survival 36 .
We next performed in vivo ubiquitination assays to determine whether MST1 induces PDX1 ubiquitination. PDX1 cotransfected with MST1, but not with MST1-K59R, was heavily ubiquitinated in HEK 293 cells. We confirmed this in human islets by showing that MST1 overexpression strongly promoted endogenous PDX1 ubiquitination ( Fig. 3d) . Subsequently, we verified a direct interaction between PDX1 and MST1 proteins. Reciprocal co-immunoprecipitations showed the interaction between MST1 and PDX1 in HEK 293 cells cotransfected with GFP-tagged PDX1 and Myc-tagged MST1 (Fig. 3e) .
We next examined whether a prodiabetic milieu regulates the association between MST1 and PDX1. Notably, both cytokine toxicity and glucotoxicity augment the interaction between MST1 and PDX1 in INS-1E cells (Supplementary Fig. 4e ). As we observed that PDX1 ubiquitination and degradation required MST1 kinase activity, we tested whether MST1 directly phosphorylates PDX1. In vitro kinase assays showed that MST1 efficiently phosphorylated PDX1; these included autoradiography using radiolabeled 32 P (Supplementary Fig. 4f) , as well as nonradioactive kinase assays and western blotting using an antibody specific to pan-phosphorylated threonine (Fig. 3f) . We confirmed the in vitro kinase assays in HEK 293 cells; coexpression of MST1 and PDX1 led to PDX1 phosphorylation (Supplementary Fig. 4f ). Together, these results establish PDX1 as a substrate for MST1.
We determined the potential MST1-targeted phosphorylation sites on PDX1 theoretically with the NetPhos 2.0 program 37 . This identified six candidate sites within the PDX1 sequence; T11, T126, T152, T155, T214 and T231 (based on the probability that a phosphosite is a substrate of MST1, given as relative score) ( Supplementary Fig. 4g ). These six sites were individually mutated to alanine to generate phosphodeficient constructs as described previously 38 . We subcloned them into pGEX bacterial expression vectors. PDX1-GST fusion proteins with the six different PDX1 mutations were purified from bacteria and used as substrates for MST1 in the kinase assay. With the exception of PDX1-T11A, WT recombinant PDX1 and the other mutants proteins were efficiently phosphorylated at threonine (Supplementary Fig. 4h ). To confirm this, we transfected all PDX1 mutant plasmids into HEK 293 cells, immunoprecipitated them with a PDX1-specific antibody and incubated them with recombinant MST1 in a kinase assay. MST1 highly phosphorylated PDX1-WT and other mutant proteins, but phosphorylation in the PDX1-T11A mutant was markedly lower (data not shown), indicating that T11 is the major site of phosphorylation by MST1.
In order to confirm T11 as the specific phosphorylation site, we used a phosphospecific antibody against the T11 phosphorylation site in PDX1, which recognized T11 phosphorylation after co-incubation of recombinant PDX1-GST fusion protein with recombinant GST-MST1 (Supplementary Fig. 4h) . Consistent with this, co-incubation of immunoprecipitated PDX1-WT or PDX1-T11A with recombinant MST1 resulted in robust MST1-induced PDX1-WT phosphorylation at the T11 site (shown by antibody to pT11) and in overall threonine phosphorylation (shown by antibody to pan-phosphorylated threonine); PDX1-T11 phosphorylation was markedly reduced in the PDX1-T11A mutant protein (Fig. 3g) . We further corroborated this by an in vivo kinase assay (Supplementary Fig. 4h ). Alignment of the amino acid sequences of PDX1 from different species revealed that the T11 site is highly conserved among those species (Supplementary Fig. 4i ).
If T11 is the specific MST1-induced phosphorylation site of PDX1 and is responsible for beta cell dysfunction, one would expect that mutated PDX1-T11A would reverse beta cell dysfunction. MST1 induced a rapid degradation of exogenous WT PDX1 in the presence of CHX that did not occur in PDX1-T11A mutant-transfected cells (Fig. 3g) . Furthermore, the half-life of the PDX1-T11A mutant was similar to that of PDX1-WT in the absence of MST1 (data not shown). Consistent with these data, there was less PDX1 ubiquitination in the PDX1-T11A-transfected cells than in those transfected with PDX1-WT (Supplementary Fig. 4j) .
Because T11 is located within the transactivational domain of PDX1 and to evaluate the functional significance of the T11-dependent ubiquitination and degradation, we assessed transcriptional activity of PDX1. Reduction of PDX1 transcriptional activity occurred only in PDX1-WT-but not in PDX1-T11A-transfected cells ( Supplementary  Fig. 4j ). As the T11A mutation of PDX1 prolongs PDX1 stability in the presence of MST1, we asked whether PDX1 stability is directly linked to improved beta cell function. PDX1-T11A mutant overexpression (Fig. 3h) normalized MST1-induced impairment in GSIS in human islets ( Fig. 3i) and INS-1E cells (Supplementary Fig. 4j ) and restored MST1-induced downregulation of PDX1 target genes ( Fig. 3j and  Supplementary Fig. 4j) . These findings indicate that MST1-induced PDX1 phosphorylation at T11 leads directly to PDX1 destabilization and impaired beta cell function and suggest that PDX1 is a crucial target of MST1 in the regulation of beta cell function.
MST1 deficiency improves beta cell survival and function
Further analyses aimed to prove whether MST1 not only mediated beta cell death and impaired function in vitro but also, when downregulated, allowed for rescue from beta cell failure ( Fig. 4  and Supplementary Fig. 5) . First, about 80% depletion of MST1 in human islets, achieved with siRNA, protected from cytokine and hydrogen peroxide toxicity as well as glucolipotoxicity; beta cell apoptosis was also inhibited (Fig. 4a,b and Supplementary Fig. 5a ). Silencing of MST1 also significantly reduced BIM upregulation induced by diabetogenic conditions in human islets (Fig. 4b,c and Supplementary Fig. 5a) .
Second, beta cell function was greatly improved by MST1 gene silencing under diabetogenic conditions ( Fig. 4d and Supplementary  Fig. 5) . Notably, IL/IF-and high glucose + palmitate (HG/Pal)induced cleavage of caspase-3 and caspase-9 and phosphorylation of H2B was lower in MST1-depleted human islets than in control islets (Fig. 4b) . Mst1 −/− islets were largely resistant to IL/IF-and HG/Pal-mediated apoptosis, as determined by TUNEL staining (Fig. 4e) . In addition to the protective effect of Mst1 knockout on beta cell survival, Mst1 −/− islets also showed improved GSIS after long-term culture with IL/IF and HG/Pal ( Fig. 4f and Supplementary  Fig. 5 ). To further support the role of MST1 as a main mediator of apoptosis in beta cells, we generated INS-1E cells stably transfected with vectors carrying Mst1-targeting shRNA (shMst1) or scrambled control shRNA (shScr) and found that Mst1 expression in cells stably expressing shMst1 was about 70% lower than that in cells npg expressing shScr (Fig. 4g) . We treated INS-1E clones with IL/IF and HG for 72 h. Bim induction, caspase-3 and PARP cleavage in Mst1-depleted cells were significantly lower than that in control cells (Fig. 4g) . Additionally, Mst1 silencing also abrogated caspase-3 and PARP cleavage induced by palmitate (Supplementary Fig. 5b ) and hydrogen peroxide (Supplementary Fig. 5c ). Cytochrome c release was markedly reduced in Mst1-depleted beta cells under diabetogenic conditions (Supplementary Fig. 5d,e) . A second shRNA clone targeting the Mst1 gene with comparable gene silencing efficiency confirmed the antiapoptotic effect of Mst1 silencing in INS-1E cells; Mst1 depletion markedly suppressed IL/IF-and HG-induced Bim upregulation and cleavage of caspase-3 and PARP ( Supplementary   Fig. 5f ). Confirmation the results of the shMst1 approach, inhibition of endogenous Mst1 activity by overexpression of Mst1-K59R completely inhibited glucose-induced caspase-3 and PARP cleavage in beta cells (Supplementary Fig. 5g ).
Mst1 deficiency significantly attenuated Pdx1 depletion caused by cytokine or high glucose treatment ( Fig. 4g and Supplementary  Fig. 5f) , implying that MST1 is indispensable for the reduction in amount of PDX1 induced by a diabetic milieu. Our next objective was to determine whether knockdown of Mst1 expression leads to improvement of GSIS and restoration of Pdx1 target genes in INS-1E cells under diabetogenic conditions. GSIS was significantly improved in Mst1-depleted beta cells ( Fig. 4h and Supplementary Fig. 5j ), npg whereas levels of Pdx1 target genes, for example, Slc2a2, Gck, Ins1 and Ins2, were restored in Mst1-depleted INS-1E cells (Fig. 4i) . These data prove MST1 as determinant for beta cell apoptosis and defective insulin secretion under a diabetic milieu in beta cells in vitro.
Mst1 deletion protects from streptozotocin-induced diabetes As MST1 depletion protected from beta cell apoptosis and restored beta cell function in vitro, we hypothesized that Mst1 deficiency may protect against diabetes in vivo by promoting beta cell survival and preserving beta cell mass. To test this hypothesis, we used Mst1 −/− mice. Neither body weight nor food intake differed between Mst1 −/− mice and their WT (Mst1 +/+ ) littermates (data not shown). Also, glucose tolerance, insulin tolerance and glucose-induced insulin response did not differ between WT and Mst1 −/− mice at 2 months of age (Supplementary Fig. 6a ). However, intraperitoneal (i.p.) glucose tolerance tests (GTTs) and i.p. insulin tolerance tests (ITTs) revealed slight improvement in Mst1 −/− mice at 6 months of age at 60 min after glucose or insulin injection (Supplementary Fig. 6b ). We induced diabetes by multiple low-dose (MLD) streptozotocin (STZ) injections in Mst1 −/− mice and WT controls. Whereas MLD-STZ injection induced progressive hyperglycemia and severely impaired glucose tolerance in WT mice, blood glucose levels were significantly reduced and glucose tolerance was highly improved in Mst1 −/− mice (Fig. 5a) . The MLD-STZ treatment led to impaired insulin secretion and a decreased insulin-to-glucose ratio in WT mice, which were significantly restored in Mst1 −/− mice (Fig. 5b,c) . Islet architecture in MLD-STZ-treated WT mice was disrupted and accompanied by less insulin-positive area, a smaller beta cell fraction, lower islet density, smaller islet size and lower beta cell mass compared to that of non-MLD-STZ-treated mice. In contrast, islet architecture of MLD-STZ-treated Mst1 −/− mice had a close to normal appearance, and beta cell fraction, islet density and beta cell mass were similar to those in non-MLD-STZ-treated mice (Fig. 5d,e and  Supplementary Fig. 6c ). Islet size also tended to be higher in MLD-STZ-injected Mst1 −/− mice than in WT mice, although this effect was not statistically significant (Supplementary Fig. 6c ).
To elucidate how MST1 deletion may affect beta cell mass, we studied beta cell apoptosis and proliferation. TUNEL staining demonstrated that the rate of apoptosis was dramatically higher in MLD-STZ-treated WT mice than in treated Mst1 −/− mice; the Mst1 deletion markedly lowered the rate of apoptosis. Beta cell proliferation was higher in MLD-STZ-treated WT mice compared to untreated WT mice, but treated Mst1 −/− beta cells showed even higher proliferation, indicative of an improved compensatory capacity ( Fig. 5d and Supplementary Fig. 6d,e) . No difference in the frequency of proliferating beta cells was observed between islets from Mst1 −/− mice and those from their WT littermates at basal levels. These results suggest that Mst1 deletion boosts beta cell mass and islet density predominantly as a result of lower rates of beta cell apoptosis and higher beta cell proliferation in response to diabetogenic stimulation.
To further assess the effect of MLD-STZ, we performed immunohistochemical analyses of insulin and glucagon on pancreatic sections. Islet cells from MLD-STZ-treated WT mice were architecturally distorted, containing significantly fewer insulin-positive cells and proportionally more glucagon-positive cells, which resulted in a higher alpha cell-to-beta cell ratio compared to untreated WT mice (Fig. 5e) . This is consistent with the previously reported alpha cell hyperplasia in diabetes 39, 40 . In contrast, the number of glucagon-positive alpha cells in MLD-STZ-injected Mst1 −/− islets was not higher and confined to the rim of the islets, suggesting that the architecture of MLD-STZinjected Mst1 −/− islets was close to normal (Fig. 5e) . In line with our in vitro results in beta cells, where MST1 acts through changes in BIM, expression of the latter was clearly seen in beta cells in diabetic MLD-STZ-treated WT mice, but not in treated Mst1 −/− mice (Fig. 5f) .
We next examined Pdx1 as a beta cell-specific MST1 substrate whose expression is regulated by both its abundance and its subcellular localization in diabetic conditions 19 . Whereas MLD-STZ-treated WT mice showed a reduced nuclear localization of Pdx1 in beta cells, Pdx1 expression was normalized and the prominent nuclear localization important for its functionality reestablished in MLD-STZ-treated Mst1 −/− mice (Fig. 5g) . The expression of the Pdx1 target Glut2 in beta cells was largely preserved in the MLD-STZ-treated Mst1 −/− mice, whereas it was barely detectable in the beta cells of MLD-STZ-treated WT mice (Supplementary Fig. 6f) . These findings suggest that Mst1 deletion preserves Pdx1 and Glut2 expression in beta cells and thus preserves the function of beta cells in the MLD-STZ model of diabetes.
To directly assess the protective effect of Mst1 deletion in MLD-STZ-induced beta cell apoptosis, we treated isolated mouse islets and INS-1E cells with STZ in vitro and found that STZ strongly induced phosphorylation of Mst1, Bim expression and ultimately apoptosis, and such apoptotic induction by STZ was attenuated by Mst1 depletion ( Supplementary Fig. 6g,h) , consistent with the in vivo observations in Mst1 −/− mice.
To exclude a secondary effect of the Mst1 deletion on beta cells, we generated mice with beta cell-specific knockout of Mst1 by the Cre-loxP system (hereafter referred to as bMst1 −/− mice). These mice contained a null mutation for Mst1 only in beta cells, as confirmed by western blotting of lysates from isolated islets (Supplementary Fig. 7a ). bMst1 −/− mice were viable, fertile and showed no difference in food intake and body weight (data not shown), glucose tolerance or insulin sensitivity compared to Mst1 fl/fl mice, which do not express Cre (Supplementary Fig. 7b,c) , or loxP-negative mice (RIP-Cre mice; data not shown). To assess whether bMst1 −/− mice might also be protected against diabetes, we again used the model of MLD-STZinduced diabetes. After MLD-STZ treatment, blood glucose levels in Mst1 fl/fl and RIP-Cre control mice increased gradually (Fig. 5h) . Whereas both control groups became overtly diabetic, reaching blood glucose levels >400 mg/dl, bMst1 −/− mice maintained normal blood glucose levels. Mst1 fl/fl and RIP-Cre control mice exhibited impaired glucose tolerance; this was notably prevented in bMst1 −/− mice (Fig. 5h) . This protection was accompanied by significant restoration of glucose-induced insulin response and insulin-to-glucose ratio (Fig. 5i) . Beta cell protection was also confirmed by the considerably higher beta cell mass in the MLD-STZ-treated bMst1 −/− mice, resulting from enhanced beta cell survival and proliferation (Fig. 5j) , compared to Mst1 fl/fl and RIP-Cre control mice. These data indicate that beta cell-specific disruption of Mst1 prevented progressive hyperglycemia and improved glucose tolerance in MLD-STZtreated mice as a result of less apoptosis and restoration of beta cell mass, suggesting that beta cell-specific activation of Mst1 is a key event in the progressive loss of beta cells in diabetes.
Mst1 deletion protects from HFD-induced diabetes
We further confirmed the protective effect of Mst1 deletion against hyperglycemia and development of diabetes in a mouse model of T2D. We fed bMst1 −/− mice and RIP-Cre controls a normal diet (ND) or a HFD for 20 weeks. Mice fed a HFD gained more weight than the ND-fed group. Beta cell-specific disruption of Mst1 had an effect on neither weight gain nor food intake in both groups ( Supplementary  Fig. 7d,e) . HFD feeding increased fed and fasted glucose levels (Fig. 6a,b ) and impaired glucose tolerance (Fig. 6b) in the HFDtreated RIP-Cre control mice compared to ND-fed mice, whereas HFD-treated bMst1 −/− mice showed significantly lower fed and fasted glucose levels as well as improved glucose tolerance (Fig. 6a,b) .
In RIP-Cre mice on a HFD, insulin secretion during i.p. glucose challenge was markedly attenuated compared with that of the NDfed group. In contrast, HFD-induced impairment in GSIS was dramatically reversed in mice with beta cell-specific deletion of Mst1 (Fig. 6c) . For assessing beta cell glucose responsiveness, we isolated islets from all ND-and HFD-fed groups. Whereas GSIS was severely impaired in islets isolated from HFD-treated RIP-Cre mice compared with ND-treated RIP-Cre mice, islets from bMst1 −/− mice remained fully responsive to glucose with improved insulin secretion under the HFD (Fig. 6d) . Consistent with the improved metabolic phenotype of bMst1 −/− mice on HFD, bMst1 −/− mice had a higher compensatory beta cell mass relative to WT HFD control mice (Fig. 6e) . The combination of lower rate of beta cell apoptosis and elevated beta cell proliferation (Fig. 6e) in bMst1 −/− mice on the HFD, which accounts a r t i c l e s 3 9 4 VOLUME 20 | NUMBER 4 | APRIL 2014 nature medicine for the higher beta cell mass in bMST1 −/− mice under the HFD, correlates with the improved glucose tolerance and insulin secretion. This is also supported by results from an i.p. ITT: glucose levels were normalized to the basal levels before insulin injection, and bMst1 −/− mice and RIP-Cre control mice on HFD showed a similar impairment in insulin sensitivity (Supplementary Fig. 7f,g) .
To test whether knockdown of MST1 expression could directly rescue beta cells, we transfected islets isolated from 10-week-old obese db/db mice and their heterozygous littermates with scrambled control siRNA or Mst1 siRNA. Whereas Scr siRNA-treated isolated islets from db/db mice showed low Pdx1 expression and high caspase-3 cleavage and Bim expression, Mst1 silencing restored Pdx1, inhibited Bim upregulation and dramatically reduced caspase-3 cleavage (Supplementary Fig. 8 ).
DISCUSSION
Our work shows that MST1 acts as an essential apoptotic molecule in the presence of diabetic stimuli and is a common component in the diverse signaling pathways leading to impaired beta cell survival in diabetes. We identified PDX1 as a beta cell-specific substrate for MST1. PDX1 ubiquitination and subsequent degradation, resulting from inhibitory T11 phosphorylation, is crucial for beta cell dysfunction after MST1 hyperactivation in diabetes (Fig. 6f) . Deletion of Mst1 preserves beta cell function and survival providing protection from diabetic insults.
MST1 has a central role in the initiation of cell death 9, [41] [42] [43] [44] . In line with our data, Mst1 ablation in vivo resulted in resistance to apoptosis induced by tumor necrosis factor-α 45 , Fas ligand 46 or IFN-γ 47 . Notably, suppression of endogenous Mst1 by cardiac-specific overexpression of the dominant-negative form of MST1 prevented cardiomyocyte death induced by ischemia-reperfusion 48 , which supports the pathophysiological significance of MST1. The diversity of diabetic stimuli by which MST1 is activated in beta cells suggests that this enzyme may be a common component in the many signaling pathways leading to beta cell apoptosis. Although the endogenous molecules that trigger MST1 activation remain unknown, we show that MST1 is highly active in a diabetic environment and induces the mitochondrial-dependent apoptosis pathway in beta cells through targeting BIM, which leads to alterations in BCL-2/BAX or BCL-xL/BAX ratios, cytochrome c release, subsequent caspase-9 and caspase-3 cleavage and cell death. Active MST1 triggers cytochrome c release and mitochondrial-dependent apoptosis by modulating Bim/Bax/Bcl-2/Bcl-xL through JNK-AKT signaling. Active caspase-9 then triggers cleavage of caspase-3, which triggers the caspase-3-dependent cleavage of MST1 to its constitutively active fragment, which leads to further MST1 activation and processing of caspase-3 by a positive feedback mechanism, and acceleration of beta cell death occurs. Cleaved MST1 translocates to the nucleus and directly phosphorylates PDX1 (we do not exclude the possibility that MST1 targets PDX1 also in cytoplasm) and histone H2B. PDX1 then shuttles to cytosol, where it undergoes ubiquitination and subsequent degradation by proteasome machinery, and beta cell function is impaired. Histone H2B phosphorylation by MST1 also induces chromatin condensation, one of the characteristic features of apoptosis. The PI3K-AKT pathway has a critical role in the regulation of beta cell survival. AKT-mediated phosphorylation of multiple substrates positively regulates insulin transcription, insulin secretion and beta cell growth and survival 21, 22, 49 . Recent studies suggest potential crosstalk between MST1 and AKT 23, 24 . MST1 activity is negatively regulated by AKT-mediated phosphorylation at its T120 and T387 residues, which results in inhibition of its cleavage, autophosphorylation, kinase activity and nuclear translocation 23 . On the other hand, MST1 and its cleaved form interact with AKT1 and act as direct AKT1 inhibitors 24 . Our data demonstrate that activation of the PI3K-AKT pathway in beta cells abrogates glucose-and cytokine-induced MST1 activation and beta cell apoptosis, whereas suppression of PI3K-AKT signaling induces MST1 activity and beta cell apoptosis. AKT and MST1 are components of two parallel stress-triggered signaling pathways that functionally antagonize each other. Activated AKT itself downregulates MST1 function in beta cells, indicating the existence of a potential bidirectional crosstalk between these two pathways.
Here, we show that MST1 and AKT negatively regulate each other and constitute a stress-sensitive survival pathway. Under acute stress conditions, AKT promoted cell survival by inhibiting MST1, but prolonged stress decreased AKT activity, which allowed for proapoptotic MST1 signaling.
MST1 may affect signal pathways of diabetic stimuli through modulation of transcription factors and gene expression profiles that initiate the process of beta cell failure. In this study, we show that MST1 can physically interact with and phosphorylate PDX1. Targeted disruption of PDX1 in beta cells leads to diabetes, and reducing its expression affects insulin expression and secretion 50 . We have identified the T11 residue of PDX1 as the phosphorylation site used by MST1. Such a kinase-dependent function would be consistent with the comparably low level of PDX1 and high levels of active MST1 in stressed beta cells and pancreases of diabetic mice in our study. PDX1 is restored by deletion of Mst1 under diabetic conditions. T11 is found in the highly conserved region of PDX1 at the transcription activation domain. T11 phosphorylation of PDX1 by MST1 marks PDX1 for degradation by the proteasome machinery, which would prohibit it from functioning as a transcription factor in the nucleus. In that regard, overexpression of MST1 caused reduction of PDX1 target gene expression and impairment of beta cell function, as assessed by GSIS, whereas mutation of the T11 site allowed PDX1 to be more stabilized and resistant to MST1-induced degradation, restoring PDX1-induced gene expression and improvement of beta cell function. The same site (T11) was previously shown to be targeted by DNA-dependent protein kinase. Consistent with our data, phosphorylation of PDX1 by this kinase results in enhanced PDX1 protein degradation 51 . PDX1 is degraded by the ubiquitin-proteasome pathway; PDX1 C terminal-inhibiting factor-1 (PCIF1) targets PDX1 for ubiquitination and proteasomal degradation by the E3 ubiquitin ligase cullin 3. Ubiquitination of PDX1 regulates its activity, as Pcif1 deficiency normalizes Pdx1 protein levels and improves glucose homeostasis and beta cell function in Pdx1 +/mice 36 . Notably, accumulation of polyubiquinated proteins was higher in beta cells of individuals with T2D than in nondiabetic controls 52 , highlighting that higher expression of polyubiquinated proteins may contribute to beta cell dysfunction under diabetic conditions.
In mammals, the absolute number of beta cells reflects a dynamic balance between beta cell growth and death. An inadequate expansion of beta cell mass to compensate for the increased insulin demand, followed by the eventual loss of beta cells due to apoptosis, is a hallmark of diabetes 4, 53 . This is most apparent in T1D when ongoing autoimmunity causes destruction and consequent loss of beta cells. Through deletion of the MST1-mediated death signal, we have uncovered a deleterious action of MST1 that induces apoptosis in response to diabetic injuries in the immune-mediated beta cell destruction in the MLD-STZ model, a model of beta cell demise that occurs in the absence of insulin resistance. Mst1 deletion not only prevents MLD-STZ-induced beta cell death but also improves the capacity of beta cells to produce insulin. Mst1 deletion preserves beta cell mass, improves beta cell function and prevents islet deterioration, as shown by the maintenance of the islet structure, density, size and mass. The observed ability to preserve islet appearance is associated with a protective role for Mst1 deficiency in MLD-STZ-induced beta cell death and in enhancing beta cell proliferation.
Preservation of PDX1 is one mechanism involved in the protection of beta cells by MST1 depletion. This conclusion is strongly supported by our in vitro and in vivo data; Pdx1 target gene expression is normalized and Glut2 localization is preserved in Mst1 −/− mice. As both Pdx1 and Glut2 are involved in glucose sensing and GSIS, Mst1 −/− mice show normal blood glucose levels and high circulating insulin concentrations. STZ enters beta cells via Glut2. It is unlikely that the resistance of Mst1 −/− mice to MLD-STZ-induced beta cell damage is due to changes in membrane Glut2 expression in beta cells because Mst1 deletion did not reduce membrane expression of Glut2 in beta cells in mice without STZ treatments.
The high rate of apoptosis in the Mst1-deficient thymocytes further illustrates the cell type-specific variation in the outputs of MST1 signaling. Whereas in thymocytes and T cells deletion of Mst1 increases the apoptosis rate [54] [55] [56] , possibly through high levels of reactive oxygen species, Mst1-deficient hepatocytes and microglia exhibit a marked resistance to stress-induced apoptosis 46, 47 . Thus, the consequences of Mst1 deficiency need to be established in each cell type and tissue. We used a tissue-specific gene-targeting approach in the current study to provide insights into the biological role of Mst1 in beta cells in vivo. It is known that activation and migration of both T cells and macrophages play an important part in islet destruction leading to hyperglycemia in the MLD-STZ model 57 . Infiltrating macrophages and T cells are a major source of the proinflammatory cytokines that promote islet destruction. Thus, the depletion of peripheral T cells in Mst1 −/− mice 54,55 might be a reason for their protection from MLD-STZ-induced hyperglycemia. We cannot exclude such T cell depletion in our model, but if it occurs, it only has a minor role, as beta cell-specific deletion of Mst1 in mice completely protected them from hyperglycemia and islet destruction. This shows that Mst1 ablation in beta cells, but not in other tissues, is a major reason for the protection from MLD-STZ-induced diabetes. Notably, beta cell-specific deletion of Mst1 in this model led to protection against beta cell apoptosis and diabetes, further underlining the critical role of MST1 in beta cell survival.
The detrimental effects of a long-term HFD on beta cell function and insulin sensitivity leading to glucose intolerance and T2D in mice have been clearly established 58 . As expected, long-term HFD feeding was associated with insulin resistance, glucose intolerance, beta cell dysfunction and loss of compensatory beta cell adaptation. As observed in the MLD-STZ model, in the HFD diabetes model, beta cell-specific Mst1 deletion results in improved glucose tolerance, insulin secretion and beta cell mass as a result of improved beta cell survival and proliferation, whereas insulin sensitivity is not affected. We have not investigated whether Mst1 is also activated in other organs during diabetes progression, but activated Mst1 has been found in the kidneys of hyperglycemic insulin receptor substrate-2 knockout mice 59 and in epididymal fat pads of HFD-treated mice 60 .
npg Our findings raise the possibility that MST1 hyperactivity is associated with beta cell failure and development of diabetes. Current therapies for the treatment of diabetes mellitus are directed toward alleviating the symptoms of the disease, but there is an urgent medical need for therapies that slow or prevent the loss (rapid in T1D, progressive in T2D) of functional pancreatic beta cell mass. In light of the critical role of MST1 in beta cell failure and initiation of prodiabetic milieu-induced apoptotic signaling, therapeutic strategies designed to inhibit MST1 activity may both protect beta cells against the effects of autoimmune attack in T1D and preserve beta cell mass and function in T2D.
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